Stay updated on Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.

Latest updates to the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%
- Check13 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new medical terms related to treatment techniques. Notably, the drug pembrolizumab has been reintroduced, indicating a focus on specific therapeutic options.SummaryDifference2%
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
- Check49 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
Stay in the know with updates to Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.